Cardiac Biomarkers Market - Growth, Trends, and Forecasts (2023 - 2028)

The cardiac biomarkers market is poised to register a CAGR of 8.5% during the forecast period (2022-2027).

The market was significantly impacted by the COVID-19 pandemic. According to a study titled "Role of Cardiac Biomarkers in COVID-19: What Recent Investigations Tell Us," published in Current Problems in Cardiology (October 2021), in the majority of the complex cases of COVID-19, cardiac injury biomarkers were elevated. This elevation is inversely correlated with the worst outcome. A more reliable tool for case fatalities and outcomes is provided by the evaluation of cardiac biomarkers in combination with markers of other organ damage. However, as per the study titled "Cardiovascular Biomarkers in Patients with COVID-19," biomarkers measuring cardiovascular pathophysiologies, such as cardiomyocyte injury and cardiac hemodynamic stress, are strongly linked to the risk of death in patients with primarily non-cardiac disorders, such as pneumonia caused by SARS-CoV-2 or other causes.

The cardiac biomarker market is driven by the rising burden of cardiovascular diseases, technological advances in cardiac biomarkers, and growing research and development funding. For instance, according to a WHO article published in July 2021, an estimated 17.9 million people worldwide die from heart disease each year. This represents 31% of all deaths worldwide. This high prevalence of cardiovascular diseases is expected to drive the demand for early diagnosis and treatment, which may expand the scope of the market studied over the forecast period.

The technological advances in cardiac biomarkers are also anticipated to boost the market. For instance, in April 2021, Roche launched a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology, i.e., high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold-standard biomarkers have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks (cTnT-hs) and better manage heart failure (NT-proBNP).

Cardiac Biomarkers Market Trends

Troponin Expected to Show High Growth

Troponin tests are becoming a lucrative market due to their benefits in detecting myocardial infarction and congestive heart failure and their efficiency in diagnosing cardiovascular disorders in a timely and accurate manner compared to other tests. According to the study published in the National Library of Medicine by Saikrishna Patibandla in August 2021, cardiac troponins are the preferred blood test to evaluate patients suspected of having acute myocardial infarction and cardiac heart failure. This is because they are specific and sensitive biomarkers of cardiac ischemia. The levels of cardiac troponin in the blood can be detected using sensitive and highly sensitive assays.

The growing burden of cardiac diseases is anticipated to drive the demand for the troponin biomarkers segment. For instance, according to the study published in Frontiers in Cardiovascular Medicine in September 2021 (Bin Yu et al.), in United States, a myocardial infraction occurs every 40 seconds, with an estimated annual incidence of 605,000 new cases and 200,000 recurrent cases and a prevalence of 3.0% among adults aged 20 years and older.

Many companies are focusing on developing breakthrough products for the treatment of cardiovascular diseases. For instance, in April 2021, Siemens Healthineers earned the CE Mark for its cardiac troponin point-of-care test. The Atellica VTLi Patient-Side Immunoassay Analyzer is a device that offers a point-of-care test to help diagnose heart attacks.

North America Dominates the Market

North America has a better healthcare infrastructure than other regions worldwide. The high burden of cardiovascular diseases in the region and the increased spending on the research and development of cardiovascular treatments are expected to drive the cardiac biomarkers market in the region during the forecast period.

According to the Centers for Disease Control and Prevention (CDC) (May 2022), COVID-19 patients with an underlying heart condition are likely to become severely ill. Additionally, according to the American College of Cardiology (ACC), people who have an underlying cardiovascular disease have a higher mortality rate when it comes to COVID-19 (10.5%) than people who have an underlying chronic respiratory disease (6.3%). Also, according to the Centers for Disease Control and Prevention (CDC)'s article titled "Heart Disease Facts," updated in September 2020, heart disease is the leading cause of death in United States. The same source also reports that about 805,000 Americans experience heart attacks every year.

There are initiatives that aim to create disease awareness, which is projected to support the market for cardiovascular devices in the North American region. For instance, in 2020, Mexico joined the HEARTS initiative to strengthen primary healthcare for cardiovascular diseases. Promoted by the Pan American Health Organization/World Health Organization (PAHO/WHO), the initiative aims to improve the prevention and control of hypertension at the primary care level.

Cardiac Biomarkers Market Competitive Analysis

The global players in the cardiac biomarkers market are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific. These companies are focused on achieving growth through the development of innovative products and new tests and improving the specificity of their tests.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support